MA45987A - Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation - Google Patents

Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation

Info

Publication number
MA45987A
MA45987A MA045987A MA45987A MA45987A MA 45987 A MA45987 A MA 45987A MA 045987 A MA045987 A MA 045987A MA 45987 A MA45987 A MA 45987A MA 45987 A MA45987 A MA 45987A
Authority
MA
Morocco
Prior art keywords
compositions
methods
receptor agonists
ht2c receptor
ht2c
Prior art date
Application number
MA045987A
Other languages
English (en)
Inventor
Michelle Kasem
Albert S Ren
Thomas O Schrader
Graeme Semple
Xiuwen Zhu
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA45987A publication Critical patent/MA45987A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045987A 2016-08-19 2017-08-18 Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation MA45987A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662377119P 2016-08-19 2016-08-19

Publications (1)

Publication Number Publication Date
MA45987A true MA45987A (fr) 2019-06-26

Family

ID=59799461

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045987A MA45987A (fr) 2016-08-19 2017-08-18 Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation

Country Status (14)

Country Link
US (2) US10836764B2 (fr)
EP (1) EP3500570B1 (fr)
JP (1) JP6977024B2 (fr)
KR (1) KR20190049732A (fr)
CN (1) CN109952301B (fr)
AU (1) AU2017313908C1 (fr)
BR (1) BR112019003142A2 (fr)
CA (1) CA3033142A1 (fr)
EA (1) EA038219B1 (fr)
IL (1) IL264682B (fr)
MA (1) MA45987A (fr)
MX (1) MX391442B (fr)
NZ (1) NZ750469A (fr)
WO (1) WO2018035477A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10836764B2 (en) * 2016-08-19 2020-11-17 Arena Pharmaceuticals, Inc. 5-HT2C receptor agonists and compositions and methods of use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CN112996795B (zh) 2018-09-18 2024-11-12 尼坎治疗公司 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
WO2020072675A1 (fr) 2018-10-02 2020-04-09 Northwestern University Bêta-carbolines servant de modulateurs allostériques positifs du récepteur humain de la sérotonine 2c (5-ht2c)
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4178569A4 (fr) * 2020-07-10 2024-07-31 Eleusis Therapeutics US, Inc. Méthode de traitement pour perfusion de psilocybine ou de psilocine
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
WO1992001029A1 (fr) 1990-07-03 1992-01-23 Quaker Chemical Corporation Agent de refroidissement aqueux
WO1992018005A1 (fr) 1991-04-16 1992-10-29 National Institutes Of Health Procede de traitement de la trichotillomanie et de l'onychophagie
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
CA2482195A1 (fr) 2002-04-12 2003-10-23 The University Of Chicago Agonistes de recepteur active frx (farnesoid x receptor)
EP2789338A3 (fr) * 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
KR20180118801A (ko) * 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
WO2015066344A1 (fr) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
WO2015161283A1 (fr) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Lactames tricycliques à utiliser dans des traitements de la prolifération de cellules anormales rb-positives, épargnant les cellules souches et les cellules progénitrices hématopoïétiques (hspc)
US10836764B2 (en) * 2016-08-19 2020-11-17 Arena Pharmaceuticals, Inc. 5-HT2C receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
AU2017313908A1 (en) 2019-02-28
IL264682B (en) 2021-08-31
WO2018035477A1 (fr) 2018-02-22
US11608339B2 (en) 2023-03-21
AU2017313908C1 (en) 2022-06-09
AU2017313908B2 (en) 2021-10-21
US20190225612A1 (en) 2019-07-25
JP2019524844A (ja) 2019-09-05
EP3500570A1 (fr) 2019-06-26
KR20190049732A (ko) 2019-05-09
BR112019003142A2 (pt) 2019-05-21
NZ750469A (en) 2023-03-31
MX2019002020A (es) 2019-11-25
US10836764B2 (en) 2020-11-17
CN109952301B (zh) 2022-03-25
EA201990527A1 (ru) 2019-07-31
MX391442B (es) 2025-03-21
CN109952301A (zh) 2019-06-28
EA038219B1 (ru) 2021-07-26
EP3500570B1 (fr) 2022-10-05
US20210214355A1 (en) 2021-07-15
JP6977024B2 (ja) 2021-12-08
CA3033142A1 (fr) 2018-02-22

Similar Documents

Publication Publication Date Title
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation
MA45996A (fr) Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3402549A4 (fr) Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
EP3373969A4 (fr) Composés interagissant avec le glycane et méthodes d'utilisation
EP3684361A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
EP3600325A4 (fr) Nouvelles compositions et méthodes
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
IL255171A0 (en) 5-Hydroxytryptamine 2-C receptor agonists. and preparations and methods of use
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
EP3316894A4 (fr) Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3525764A4 (fr) Composition orale d'extraits de cannabinoïdes et procédés d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA42527A (fr) Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
EP3364984A4 (fr) Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
MA44087A (fr) Immunothérapie basée sur la listéria et ses méthodes d'utilisation
EP3510380A4 (fr) Composés sondes par activité, compositions et méthodes d'utilisation
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
EP3829307A4 (fr) Compositions de bismuth-thiol et méthodes d'utilisation
EP3373907A4 (fr) Compositions pharmaceutiques à libération prolongée et méthodes d'utilisation